These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 29732468)

  • 21. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; MacLaren RE; Downes SM; Fauser S; Boon CJF; Hoyng CB
    Am J Ophthalmol; 2020 Aug; 216():80-89. PubMed ID: 32289294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy.
    Munk MR; Shah R; Pappas F; Baddar D; Wong B; Jampol LM; Fawzi AA
    Curr Eye Res; 2016; 41(1):97-106. PubMed ID: 25612245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY.
    Hu J; Qu J; Li M; Sun G; Piao Z; Liang Z; Yao Y; Sadda S; Zhao M
    Retina; 2021 Jan; 41(1):189-198. PubMed ID: 32343102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.
    van Dijk EHC; Fauser S; Breukink MB; Blanco-Garavito R; Groenewoud JMM; Keunen JEE; Peters PJH; Dijkman G; Souied EH; MacLaren RE; Querques G; Downes SM; Hoyng CB; Boon CJF
    Ophthalmology; 2018 Oct; 125(10):1547-1555. PubMed ID: 29776672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy.
    Chung CY; Chan YY; Li KKW
    Ophthalmologica; 2018; 240(1):37-44. PubMed ID: 29566395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
    Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M
    J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.
    Tseng CC; Chen SN
    Br J Ophthalmol; 2015 Aug; 99(8):1070-7. PubMed ID: 25680621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.
    Scholz P; Altay L; Fauser S
    Eye (Lond); 2016 Oct; 30(10):1371-1377. PubMed ID: 27391938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
    Lim SH; Chang W; Sagong M
    Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy.
    Shin YI; Kim KM; Lee MW; Kim JY; Jo YJ
    Jpn J Ophthalmol; 2020 Jan; 64(1):28-36. PubMed ID: 31863228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.
    Demircan A; Yesilkaya C; Alkin Z
    Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
    Goto S; Gomi F; Ueno C; Nishida K
    Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Half-time photodynamic therapy for central serous chorioretinopathy.
    Tsai MJ; Hsieh YT
    Optom Vis Sci; 2014 Sep; 91(9):1140-5. PubMed ID: 25083838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Hayashida M; Miki A; Nakai S; Matsumiya W; Imai H; Kusuhara S; Honda S; Nakamura M
    Mol Vis; 2020; 26():505-509. PubMed ID: 32774081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.